Table 3.
The age of PWS genetic diagnosis and the data at the start of rhGH treatment depending on the age of PWS molecular diagnosis (the mean value ± standard deviation score, SDS; median (minimal-maximal value) for the age of diagnosis and rhGH start).
| PWS Group | Group 1 | Group 2 | Group 3 |
|---|---|---|---|
| Number of patients (%) | n = 82 (55.8) | n = 25 (17) | n = 40 (27.2) |
| F/M (%) | 39/43 (47.56/52.44) | 13/12 (52/48) | 17/23 (42.50/57.50) |
| Age of diagnosis [years] | 0.25 ± 0.18 0.21 (0.02–0.71) |
1.35 ± 0.36 1.22 (0.79–1.93) (p = 0.00) * |
5.00 ± 2.56 4.33 (2.06–12.49) (p = 0.00) * |
| Age of rhGH start [years] | 2.60 ± 2.28 1.97 (0.58–13.09) |
4.86 ± 3.39 3.53 (1.59-12.56) (p = 0.00) * |
8.44 ± 3.43 8.28 (2.91–17.43) (p = 0.00) * |
| rhGH dose (IU/kg/week; mg/kg/day) |
0.57 ± 0.14; 0.027 ± 0.007 |
0.58 ± 0.15; 0.027 ± 0.007 |
0.60 ± 0.21; 0.029 ± 0.01 |
| Height [cm] | 84.57 ± 16.78 | 99.88 ± 21.04 | 119.81 ± 18.33 |
| Height SDS | −2.13 ± 1.52 | −2.02 ± 1.61 | −2.10 ± 1.44 |
| BMI | 16.21 ± 2.60 | 18.79 ± 3.44 | 21.52 ± 4.35 |
| BMI SDS | −0.21 ± 1.62 | 1.14 ± 1.26 (p = 0.00) ** |
1.24 ± 0.79 (p = 0.00) ** |
| IGF1 [ng/mL] | 52.46 ± 36.44 | 79.72 ± 64.76 | 101.87 ± 66.44 |
| IGF1 SDS | −0.84 ± 0.27 | −0.87 ± 0.43 | −1.01 ± 0.64 (p = 0.052) *** |
PWS—Prader–Willi syndrome, F/M—female/male, rhGH—recombinant human growth hormone, BMI—body mass index, IGF1—insulin-like growth factor 1, group 1: age ≤9 months, group 2: >9 months ≤2 years, group 3: >2 years of life, * group 2 vs. 1, group 3 vs. 1, group 3 vs. 2, ** group 2 vs. 1, group 3 vs. 1, *** group 3 vs. 1.